After a multiyear effort to cut away roughly $3 billion in operational costs, Israeli drugmaker Teva could be expected to take a short break to its slice-and-dice efforts. Instead, Teva is keeping its foot on the gas pedal, and hundreds of Israeli manufacturing jobs are now in the chopping block.
Teva will cut 350 positions at its active pharmaceuticals ingredient (API) plant in Neot-Havav, Israel, as part of a “global optimization plan” to streamline site operations through February 2022, the drugmaker said Monday.
